133 Molesworth Street
PO Box 5013
Wellington 6140
New Zealand
T+64 4 496 2000
17 January 2022
Annie Weston
By email:
[email address]
[FYI request #17902 email]
[email address]
[email address]
[email address]
[email address]
[email address]
[email address]
[email address]
[email address]
Ref:
H202117251
Tēnā koe Annie
Response to your requests for official information
Thank you for your requests under the Official Information Act 1982 (the Act) on 3 December
2021, 6 December 2021, 7 December 2021 (10.38am, 11.15am and 12.58pm); 10 December
2021 (11.03am and 11.19am), 12 December 2021, 16 December 2021, and 20 December
2021. The two requests on 10 December 2021 were made to the Minister of Health, Hon
Andrew Little, and the request on 12 December 2021 was made to the Department of the Prime
Minister and Cabinet (DPMC), and subsequently transferred to the Ministry of Health (the
Ministry) response.
As these requests all relate to the Pfizer Comirnaty COVID-19 vaccine, the Ministry has
consolidated your requests under section 16 of the Act. Your consolidated request is attached
as Appendix 1.
Given the size of your consolidated request, which runs to 10 pages, it might be refused under
section 18 of the Act on the grounds that it would require the substantial collation of information.
However, as required under section 18A of the Act, the Ministry is seeking under section 15 of
the Act to provide you with the opportunity to rescope your request. In asking you to rescope
your request, the Ministry asks you to consider the following points.
The first point concerns the nature of requests under the Act. While the law allows New
Zealanders to request official information from Ministers and government agencies, there is no
requirement under the Act for the Ministry to create new information, compile information it does
not hold, provide or prove an opinion or respond to hypothetical questions. Several of your
questions are asking the Ministry to offer comment on statements made overseas or vaccine
requirements in foreign jurisdictions. The Act does support requests where an opinion, comment
or statement is put to the Ministry for response, couched as a request for information. Some of
your questions fall into this category and are likely to be refused.
Secondly, since the global pandemic began, the Ministry and other government agencies have
proactively published a significant amount of information about COVID-19 that would answer
many of your questions. I want to draw your attention to the following:
• Comprehensive information about New Zealand’s COVID-19 response, including
vaccination, alert levels, overseas travel and departure tests, is available on the
Unite
against COVID-19 website at:
www.covid19.govt.nz.
• The Department of the Prime Minister and Cabinet is the lead agency for the Al -of-
Government response to the COVID-19 pandemic and has published information about
its work at
: ht ps://dpmc.govt.nz/our-business-units/covid-19-group.
• COVID-19 case numbers are published daily by the
Institute of Environmental Science
and Research (ESR):
https:/ nzcoviddashboard.esr.cri.nz/#!/ ESR has also published a
wide range of other information about the SARs CoV-2 virus and its response work:
www.esr.cri.nz/our-expertise/covid-19-response/.
• The Ministry also publishes
COVID-19 case data (www.health.govt.nz/our-
work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-data-and-
statistics/covid-19-current-cases), COVID-19 Situation Reports
(www.health.govt.nz/about-ministry/information-releases/general-information-
releases/covid-19-situation-reports-january-november-2020) and COVID-19 vaccination
data (www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-
coronavirus/covid-19-data-and-statistics/covid-19-vaccine-data).
• New Zealand’s Medicines and Medical Devices Authority, Medsafe, has published a
range of information on the approval of COVID-19 vaccines, including adverse events
following immunisation (including deaths) at:
www.medsafe.govt.nz/index.asp.
Information about the voluntary reporting of adverse events is available at:
www.medsafe.govt.nz/COVID-19/q-and-a-vaccine-safety.asp#data. It has also published
the Consumer Medicine Information Summary (CMIS) that addresses your questions
about the ingredients of the Comirnaty vaccine at:
www.medsafe.govt.nz/Consumers/cmi/c/comirnaty.pdf
• Medsafe has also published information about thrombosis
(www.medsafe.govt.nz/Consumers/educational-material/Thrombosis-with-
Thrombocytopenia-Syndrome.pdf), pregnancy
(www.medsafe.govt.nz/safety/Alerts/covid-19-vaccination-in-pregnancy.asp), and
myocarditis and pericarditis
(www.medsafe.govt.nz/safety/Alerts/comirnaty-myocarditis-
alert.htm) among a range of topics.
• The Ministry has published responses to requests under the Act that cover many of the
issues you have raised at:
www.health.govt.nz/about-ministry/information-
releases/responses-of icial-information-act-requests. Specifically, several of your
questions relate to a document published in the United States, namely the
Cumulative
Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2)
Received Through 28-Feb-2021. The Ministry has received several similar requests for
information related to this document. A comprehensive response that addresses these
parts of your request is publicly available at:
www.health.govt.nz/system/files/documents/information-
release/h202117570_response_0.pdf
• The Ministry has published a review of a range of scientific information on COVID-19-
related topics at:
www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-
coronavirus/covid-19-resources-and-tools/covid-19-science-news.
• The Immunisation Handbook (chapter 5) contains a range of information and references
to scientific literature about COVID-19 and COVID-19 vaccines. It is available at:
www.health.govt.nz/our-work/immunisation-handbook-2020/5-coronavirus-disease-
covid-19
Page 2 of 13
• The Ministry has published a range of information about pregnancy and breastfeeding,
including:
www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-
coronavirus/covid-19-vaccines/covid-19-vaccine-health-advice/covid-19-vaccine-
pregnancy-and-breastfeeding
www.health.govt.nz/system/files/documents/pages/csu-13-sept-2021-vaccination-in-
pregnancy-is-not-associated-with-miscarriage.pdf
www.medsafe.govt.nz/safety/Alerts/covid-19-vaccination-in-pregnancy.asp
www.health.govt.nz/our-work/immunisation-handbook-2020/5-coronavirus-disease-
covid-19#23-4 (especially sections 5.2.2., 5.4.4. and 5.5.9. and the scientific
references in these sections).
• Additionally, a range of peer reviewed scientific research about the COVID-19 virus and
vaccines has been published on
PubMed by the National Center for Biotechnology
Information at the National Institutes of Health in the United States at:
https:/ pubmed.ncbi.nlm.nih.gov. Specifically, a search on this website for this phrase:
“Safety and Ef icacy of the BNT162b2 mRNA Covid-19 Vaccine" provides a wealth of
scientific literature on the safety and efficacy of the Pfizer Comirnaty vaccine.
I look forward to your response by
21 January 2022.
Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any
decisions made under this request. The Ombudsman may be contacted by email at:
[email address] or by calling 0800 802 602.
Nāku noa, nā
Jan Torres
Acting Manager, OIA Services
Office of the Director-General
Page 3 of 13
Appendix 1
Request – 3 December 2021
It is a simple question on your policy - it does not require opinion, comment, argument, or a
hypothetical statement. I simply want to know why the Govt does not require anyone to report
adverse effects from taking the vaccines.
Request – 6 December 2021
https://www.medsafe.govt.nz/COVID-19/active-monitoring.asp
The Post Vaccine Symptom Check was paused on 5 November 2021 in order to allow for a
review of the survey design and the data received to date. This review wil ensure the survey
can continue to support the roll-out of the vaccine into the future. Thank you to everyone who
has participated so far. The Post Vaccine Symptom Check wil resume in early December
2021.”
My questions please:
1)
Wil the Post Vaccine Symptom Check contain the data from November or was this not
collected for some reason. I am particularly interested in viewing the vaccine deaths and
injuries that occurred after the “Super Saturday” event on 16 October 2021.
2)
The full side effects that are listed and linked on the webpage stil don’t list death. When
wil you update this please?
3)
The results from the survey are likely to be displayed in October 2021 according to the
webpage which was revised on 17 November 2021. When wil they actual y be available
to view please?
Request – 7 December 2021 10.38am
Pfizer have allegedly released a 38 page document that details 100 plus new adverse events
from the vaccine that pose long term risks to health. The document was finalised on 30 April
2021 before the Govt mandated vaccines. The title of the document is as per below and at this
stage has not been censored by search engines.
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS
OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021
Questions please:
1)
Does the single source of truth determine that this is a legitimate document from Pfizer
and is not misinformation?
2)
If it is legitimate when was the Govt supplied with this information?
Request – 7 December 2021 11.15am
According to Pfizer's recently released analysis the below is a list of the adverse events of
special interest that could occur after taking their vaccine.
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS
OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021
Question please:
When wil these adverse events be added to the New Zealand Data Sheet for Comirnaty?
https://www.medsafe.govt.nz/profs/Datasheet/c/comirnatyinj.pdf
Page 4 of 13
APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST
1p36 deletion syndrome;2-Hydroxyglutaric aciduria;5'nucleotidase increased;Acoustic
neuritis;Acquired C1 inhibitor deficiency;Acquired epidermolysis bullosa;Acquired epileptic
aphasia;Acute cutaneous lupus erythematosus;Acute disseminated encephalomyelitis;Acute
encephalitis with refractory, repetitive partial seizures;Acute febrile neutrophilic
dermatosis;Acute flaccid myelitis;Acute haemorrhagic leukoencephalitis;Acute haemorrhagic
oedema of infancy;Acute kidney injury;Acute macular outer retinopathy;Acute motor axonal
neuropathy;Acute motor-sensory axonal neuropathy;Acute myocardial infarction;Acute
respiratory distress syndrome;Acute respiratory failure;Addison's disease;Administration site
thrombosis;Administration site vasculitis;Adrenal thrombosis;Adverse event following
immunisation;Ageusia;Agranulocytosis;Air
embolism;Alanine aminotransferase abnormal;Alanine aminotransferase increased;Alcoholic
seizure;Al ergic bronchopulmonary mycosis;Al ergic oedema;Al oimmune hepatitis;Alopecia
areata;Alpers disease;Alveolar proteinosis;Ammonia abnormal;Ammonia increased;Amniotic
cavity infection;Amygdalohippocampectomy;Amyloid
arthropathy;Amyloidosis;Amyloidosis senile;Anaphylactic reaction;Anaphylactic
shock;Anaphylactic transfusion reaction;Anaphylactoid reaction;Anaphylactoid
shock;Anaphylactoid syndrome of pregnancy;Angioedema;Angiopathic neuropathy;Ankylosing
spondylitis;Anosmia;Antiacetylcholine receptor antibody positive;Anti-actin antibody
positive;Anti-aquaporin-4 antibody positive;Anti-basal ganglia antibody positive;Anti-cyclic
citrullinated peptide antibody positive;Anti-epithelial antibody positive;Anti-erythrocyte antibody
positive;Anti-exosome complex antibody positive;Anti- GAD antibody negative;Anti-GAD
antibody positive;Anti-ganglioside antibody positive;Antigliadin antibody positive;Anti-glomerular
basement membrane antibody positive;Anti-glomerular basement membrane disease;Anti-
glycyl-tRNA synthetase antibody positive;Anti-HLA antibody test positive;Anti-IA2 antibody
positive;Anti-insulin antibody increased;Anti-insulin antibody positive;Anti-insulin receptor
antibody increased;Anti nsulin receptor antibody positive;Anti-interferon antibody negative;Anti-
interferon antibody positive;Anti-islet cell antibody positive;Antimitochondrial antibody
positive;Anti-muscle specific kinase antibody positive;Anti-myelin-associated glycoprotein
antibodies positive;Anti-myelin-associated glycoprotein associated
polyneuropathy;Antimyocardial antibody positive;Anti-neuronal antibody positive;Antineutrophil
cytoplasmic antibody increased;Antineutrophil cytoplasmic antibody positive;Anti-neutrophil
cytoplasmic antibody positive vasculitis;Anti-NMDA antibody positive;Antinuclear antibody
increased;Antinuclear antibody positive;Antiphospholipid antibodies positive;Antiphospholipid
syndrome;Anti-platelet antibody positive;Anti-prothrombin antibody positive;Antiribosomal P
antibody positive;Anti-RNA polymerase III antibody positive;Anti-saccharomyces cerevisiae
antibody test positive;Anti-sperm antibody positive;Anti-SRP antibody positive;Antisynthetase
syndrome;Anti-thyroid antibody positive;Anti-transglutaminase antibody increased;Anti-VGCC
antibody positive;Anti- VGKC antibody positive;Anti-vimentin antibody positive;Antiviral
prophylaxis;Antiviral treatment;Anti-zinc transporter 8 antibody positive;Aortic embolus;Aortic
thrombosis;Aortitis;Aplasia pure red cell;Aplastic anaemia;Application site
thrombosis;Application site vasculitis;Arrhythmia;Arterial bypass occlusion;Arterial bypass
thrombosis;Arterial thrombosis;Arteriovenous fistula thrombosis;Arteriovenous graft site
stenosis;Arteriovenous graft thrombosis;Arteritis;Arteritis Page 30
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (
GMT)
FDA-CBER-2021-5683-0000083
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page
2 coronary;Arthralgia;Arthritis;Arthritis enteropathic;Ascites;Aseptic cavernous sinus
thrombosis;Aspartate aminotransferase abnormal;Aspartate aminotransferase
increased;Aspartate-glutamate-transporter deficiency;AST to platelet ratio index
increased;AST/ALT ratio abnormal;Asthma;Asymptomatic COVID-
19;Ataxia;Atheroembolism;Atonic seizures;Atrial thrombosis;Atrophic thyroiditis;Atypical benign
partial epilepsy;Atypical pneumonia;Aura;Autoantibody positive;Autoimmune
anaemia;Autoimmune aplastic anaemia;Autoimmune arthritis;Autoimmune blistering
disease;Autoimmune cholangitis;Autoimmune colitis;Autoimmune demyelinating
Page 5 of 13
disease;Autoimmune dermatitis;Autoimmune disorder;Autoimmune
encephalopathy;Autoimmune endocrine disorder;Autoimmune enteropathy;Autoimmune eye
disorder;Autoimmune haemolytic anaemia;Autoimmune heparin-induced
thrombocytopenia;Autoimmune hepatitis;Autoimmune hyperlipidaemia;Autoimmune
hypothyroidism;Autoimmune inner ear disease;Autoimmune lung disease;Autoimmune
lymphoproliferative syndrome;Autoimmune myocarditis;Autoimmune myositis;Autoimmune
nephritis;Autoimmune neuropathy;Autoimmune neutropenia;Autoimmune
pancreatitis;Autoimmune pancytopenia;Autoimmune pericarditis;Autoimmune
retinopathy;Autoimmune thyroid disorder;Autoimmune thyroiditis;Autoimmune
uveitis;Autoinflammation with infantile enterocolitis;Autoinflammatory disease;Automatism
epileptic;Autonomic nervous system imbalance;Autonomic seizure;Axial
spondyloarthritis;Axil ary vein thrombosis;Axonal and demyelinating polyneuropathy;Axonal
neuropathy;Bacterascites;Baltic myoclonic epilepsy;Band sensation;Basedow's disease;Basilar
artery thrombosis;Basophilopenia;B-cell aplasia;Behcet's syndrome;Benign ethnic
neutropenia;Benign familial neonatal convulsions;Benign familial pemphigus;Benign rolandic
epilepsy;Beta-2 glycoprotein antibody positive;Bickerstaff's encephalitis;Bile output
abnormal;Bile output decreased;Biliary ascites;Bilirubin conjugated abnormal;Bilirubin
conjugated increased;Bilirubin urine present;Biopsy liver abnormal;Biotinidase
deficiency;Birdshot chorioretinopathy;Blood alkaline phosphatase abnormal;Blood alkaline
phosphatase increased;Blood bilirubin abnormal;Blood bilirubin increased;Blood bilirubin
unconjugated increased;Blood cholinesterase abnormal;Blood cholinesterase decreased;Blood
pressure decreased;Blood pressure diastolic decreased;Blood pressure systolic decreased;Blue
toe syndrome;Brachiocephalic vein thrombosis;Brain stem embolism;Brain stem
thrombosis;Bromosulphthalein test abnormal;Bronchial oedema;Bronchitis;Bronchitis
mycoplasmal;Bronchitis viral;Bronchopulmonary aspergil osis allergic;Bronchospasm;Budd-
Chiari syndrome;Bulbar palsy;Butterfly rash;C1q nephropathy;Caesarean section;Calcium
embolism;Capillaritis;Caplan's syndrome;Cardiac amyloidosis;Cardiac arrest;Cardiac
failure;Cardiac failure acute;Cardiac sarcoidosis;Cardiac ventricular thrombosis;Cardiogenic
shock;Cardiolipin antibody positive;Cardiopulmonary failure;Cardio-respiratory arrest;Cardio-
respiratory distress;Cardiovascular insufficiency;Carotid arterial embolus;Carotid artery
thrombosis;Cataplexy;Catheter site thrombosis;Catheter site vasculitis;Cavernous sinus
thrombosis;CDKL5 deficiency disorder;CEC syndrome;Cement embolism;Central nervous
system lupus;Central nervous system vasculitis;Cerebellar artery thrombosis;Cerebellar
embolism;Cerebral amyloid angiopathy;Cerebral arteritis;Cerebral artery embolism;Cerebral
artery thrombosis;Cerebral gas embolism;Cerebral microembolism;Cerebral septic
infarct;Cerebral thrombosis;Cerebral venous sinus thrombosis;Cerebral venous
thrombosis;Cerebrospinal thrombotic Page 31 090177e196ea1800\Approved\Approved On: 30-
Apr-2021 09:26 (
GMT)
FDA-CBER-2021-5683-0000084
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page
3 tamponade;Cerebrovascular accident;Change in seizure presentation;Chest discomfort;Child-
Pugh-Turcotte score abnormal;Child-Pugh-Turcotte score
increased;Chil blains;Choking;Choking sensation;Cholangitis sclerosing;Chronic autoimmune
glomerulonephritis;Chronic cutaneous lupus erythematosus;Chronic fatigue syndrome;Chronic
gastritis;Chronic inflammatory demyelinating polyradiculoneuropathy;Chronic lymphocytic
inflammation with pontine perivascular enhancement responsive to steroids;Chronic recurrent
multifocal osteomyelitis;Chronic respiratory failure;Chronic spontaneous urticaria;Circulatory
collapse;Circumoral oedema;Circumoral swelling;Clinically isolated syndrome;Clonic
convulsion;Coeliac disease;Cogan's syndrome;Cold agglutinins positive;Cold type haemolytic
anaemia;Colitis;Colitis erosive;Colitis herpes;Colitis microscopic;Colitis ulcerative;Collagen
disorder;Collagen-vascular disease;Complement factor abnormal;Complement factor C1
decreased;Complement factor C2 decreased;Complement factor C3 decreased;Complement
factor C4 decreased;Complement factor decreased;Computerised tomogram liver
abnormal;Concentric sclerosis;Congenital anomaly;Congenital bilateral perisylvian
syndrome;Congenital herpes simplex infection;Congenital myasthenic syndrome;Congenital
Page 6 of 13
varicella infection;Congestive hepatopathy;Convulsion in childhood;Convulsions
local;Convulsive threshold lowered;Coombs positive haemolytic anaemia;Coronary artery
disease;Coronary artery embolism;Coronary artery thrombosis;Coronary bypass
thrombosis;Coronavirus infection;Coronavirus test;Coronavirus test negative;Coronavirus test
positive;Corpus callosotomy;Cough;Cough variant asthma;COVID-19;COVID-19
immunisation;COVID-19 pneumonia;COVID-19 prophylaxis;COVID-19 treatment;Cranial nerve
disorder;Cranial nerve palsies multiple;Cranial nerve paralysis;CREST syndrome;Crohn's
disease;Cryofibrinogenaemia;Cryoglobulinaemia;CSF oligoclonal band present;CSWS
syndrome;Cutaneous amyloidosis;Cutaneous lupus erythematosus;Cutaneous
sarcoidosis;Cutaneous vasculitis;Cyanosis;Cyclic neutropenia;Cystitis interstitial;Cytokine
release syndrome;Cytokine storm;De novo purine synthesis inhibitors associated acute
inflammatory syndrome;Death neonatal;Deep vein thrombosis;Deep vein thrombosis
postoperative;Deficiency of bile secretion;Deja vu;Demyelinating
polyneuropathy;Demyelination;Dermatitis;Dermatitis bullous;Dermatitis
herpetiformis;Dermatomyositis;Device embolisation;Device related thrombosis;Diabetes
mellitus;Diabetic ketoacidosis;Diabetic mastopathy;Dialysis amyloidosis;Dialysis membrane
reaction;Diastolic hypotension;Diffuse vasculitis;Digital pitting scar;Disseminated intravascular
coagulation;Disseminated intravascular coagulation in newborn;Disseminated neonatal herpes
simplex;Disseminated varicella;Disseminated varicella zoster vaccine virus
infection;Disseminated varicella zoster virus infection;DNA antibody positive;Double cortex
syndrome;Double stranded DNA antibody positive;Dreamy state;Dressler's syndrome;Drop
attacks;Drug withdrawal convulsions;Dyspnoea;Early infantile epileptic encephalopathy with
burst-suppression;Eclampsia;Eczema herpeticum;Embolia cutis medicamentosa;Embolic
cerebellar infarction;Embolic cerebral infarction;Embolic pneumonia;Embolic
stroke;Embolism;Embolism arterial;Embolism venous;Encephalitis;Encephalitis
allergic;Encephalitis autoimmune;Encephalitis brain stem;Encephalitis
haemorrhagic;Encephalitis periaxialis diffusa;Encephalitis post
immunisation;Encephalomyelitis;Encephalopathy;Endocrine disorder;Endocrine
ophthalmopathy;Endotracheal intubation;Enteritis;Enteritis leukopenic;Enterobacter
pneumonia;Enterocolitis;Enteropathic spondylitis;Eosinopenia;Eosinophilic
Page 32 090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (
GMT)
FDA-CBER-2021-5683-0000085
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page
4 fasci tis;Eosinophilic granulomatosis with polyangiitis;Eosinophilic
oesophagitis;Epidermolysis;Epilepsy;Epilepsy surgery;Epilepsy with myoclonic-atonic
seizures;Epileptic aura;Epileptic psychosis;Erythema;Erythema induratum;Erythema
multiforme;Erythema nodosum;Evans syndrome;Exanthema subitum;Expanded disability status
scale score decreased;Expanded disability status scale score increased;Exposure to
communicable disease;Exposure to SARS-CoV-2;Eye oedema;Eye pruritus;Eye swelling;Eyelid
oedema;Face oedema;Facial paralysis;Facial paresis;Faciobrachial dystonic seizure;Fat
embolism;Febrile convulsion;Febrile infection-related epilepsy syndrome;Febrile
neutropenia;Felty's syndrome;Femoral artery embolism;Fibril ary
glomerulonephritis;Fibromyalgia;Flushing;Foaming at mouth;Focal cortical resection;Focal
dyscognitive seizures;Foetal distress syndrome;Foetal placental thrombosis;Foetor
hepaticus;Foreign body embolism;Frontal lobe epilepsy;Fulminant type 1 diabetes
mellitus;Galactose elimination capacity test abnormal;Galactose elimination capacity test
decreased;Gamma-glutamyltransferase abnormal;Gamma-glutamyltransferase
increased;Gastritis herpes;Gastrointestinal amyloidosis;Gelastic seizure;Generalised onset non-
motor seizure;Generalised tonic-clonic seizure;Genital herpes;Genital herpes simplex;Genital
herpes zoster;Giant cell arteritis;Glomerulonephritis;Glomerulonephritis
membranoproliferative;Glomerulonephritis membranous;Glomerulonephritis rapidly
progressive;Glossopharyngeal nerve paralysis;Glucose transporter type 1 deficiency
syndrome;Glutamate dehydrogenase increased;Glycocholic acid increased;GM2
gangliosidosis;Goodpasture's syndrome;Graft thrombosis;Granulocytopenia;Granulocytopenia
neonatal;Granulomatosis with polyangiitis;Granulomatous dermatitis;Grey matter
Page 7 of 13
heterotopia;Guanase increased;Guil ain- Barre syndrome;Haemolytic
anaemia;Haemophagocytic lymphohistiocytosis;Haemorrhage;Haemorrhagic
ascites;Haemorrhagic disorder;Haemorrhagic pneumonia;Haemorrhagic varicella
syndrome;Haemorrhagic vasculitis;Hantavirus pulmonary infection;Hashimoto's
encephalopathy;Hashitoxicosis;Hemimegalencephaly;Henoch-Schonlein purpura;Henoch-
Schonlein purpura nephritis;Hepaplastin abnormal;Hepaplastin decreased;Heparin-induced
thrombocytopenia;Hepatic amyloidosis;Hepatic artery embolism;Hepatic artery flow
decreased;Hepatic artery thrombosis;Hepatic enzyme abnormal;Hepatic enzyme
decreased;Hepatic enzyme increased;Hepatic fibrosis marker abnormal;Hepatic fibrosis marker
increased;Hepatic function abnormal;Hepatic hydrothorax;Hepatic hypertrophy;Hepatic
hypoperfusion;Hepatic lymphocytic infiltration;Hepatic mass;Hepatic pain;Hepatic
sequestration;Hepatic vascular resistance increased;Hepatic vascular thrombosis;Hepatic vein
embolism;Hepatic vein thrombosis;Hepatic venous pressure gradient abnormal;Hepatic venous
pressure gradient increased;Hepatitis;Hepatobiliary scan
abnormal;Hepatomegaly;Hepatosplenomegaly;Hereditary angioedema with C1 esterase
inhibitor deficiency;Herpes dermatitis;Herpes gestationis;Herpes oesophagitis;Herpes
ophthalmic;Herpes pharyngitis;Herpes sepsis;Herpes simplex;Herpes simplex cervicitis;Herpes
simplex colitis;Herpes simplex encephalitis;Herpes simplex gastritis;Herpes simplex
hepatitis;Herpes simplex meningitis;Herpes simplex meningoencephalitis;Herpes simplex
meningomyelitis;Herpes simplex necrotising retinopathy;Herpes simplex oesophagitis;Herpes
simplex otitis externa;Herpes simplex pharyngitis;Herpes simplex pneumonia;Herpes simplex
reactivation;Herpes simplex sepsis;Herpes simplex viraemia;Herpes simplex virus conjunctivitis
neonatal;Herpes simplex visceral;Herpes virus Page 33
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (
GMT)
FDA-CBER-2021-5683-0000086
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page
5 infection;Herpes zoster;Herpes zoster cutaneous disseminated;Herpes zoster infection
neurological;Herpes zoster meningitis;Herpes zoster meningoencephalitis;Herpes zoster
meningomyelitis;Herpes zoster meningoradiculitis;Herpes zoster necrotising retinopathy;Herpes
zoster oticus;Herpes zoster pharyngitis;Herpes zoster reactivation;Herpetic
radiculopathy;Histone antibody positive;Hoigne's syndrome;Human herpesvirus 6
encephalitis;Human herpesvirus 6 infection;Human herpesvirus 6 infection reactivation;Human
herpesvirus 7 infection;Human herpesvirus 8
infection;Hyperammonaemia;Hyperbilirubinaemia;Hypercholia;Hypergammaglobulinaemia
benign monoclonal;Hyperglycaemic seizure;Hypersensitivity;Hypersensitivity
vasculitis;Hyperthyroidism;Hypertransaminasaemia;Hyperventilation;Hypoalbuminaemia;H
ypocalcaemic seizure;Hypogammaglobulinaemia;Hypoglossal nerve paralysis;Hypoglossal
nerve paresis;Hypoglycaemic seizure;Hyponatraemic seizure;Hypotension;Hypotensive
crisis;Hypothenar hammer syndrome;Hypothyroidism;Hypoxia;Idiopathic CD4
lymphocytopenia;Idiopathic generalised epilepsy;Idiopathic interstitial pneumonia;Idiopathic
neutropenia;Idiopathic pulmonary fibrosis;IgA nephropathy;IgM nephropathy;II rd nerve
paralysis;I Ird nerve paresis;Iliac artery embolism;Immune thrombocytopenia;Immunemediated
adverse reaction;Immune-mediated cholangitis;Immune-mediated cholestasis;Immune-
mediated cytopenia;Immune-mediated encephalitis;Immune-mediated encephalopathy;Immune-
mediated endocrinopathy;Immune-mediated enterocolitis;Immunemediated gastritis;Immune-
mediated hepatic disorder;Immune-mediated hepatitis;Immunemediated
hyperthyroidism;Immune-mediated hypothyroidism;Immune-mediated myocarditis;Immune-
mediated myositis;Immune-mediated nephritis;Immune-mediated neuropathy;Immune-mediated
pancreatitis;Immune-mediated pneumonitis;Immune-mediated renal disorder;Immune-mediated
thyroiditis;Immune-mediated uveitis;Immunoglobulin G4 related disease;Immunoglobulins
abnormal;Implant site thrombosis;Inclusion body myositis;Infantile genetic
agranulocytosis;Infantile spasms;Infected vasculitis;Infective
thrombosis;Inflammation;Inflammatory bowel disease;Infusion site thrombosis;Infusion site
vasculitis;Injection site thrombosis;Injection site urticaria;Injection site vasculitis;Instil ation site
thrombosis;Insulin autoimmune syndrome;Interstitial granulomatous dermatitis;Interstitial lung
Page 8 of 13
disease;Intracardiac mass;Intracardiac thrombus;Intracranial pressure increased;Intrapericardial
thrombosis;Intrinsic factor antibody abnormal;Intrinsic factor antibody positive;IPEX
syndrome;Irregular breathing;IRVAN syndrome;IVth nerve paralysis;IVth nerve paresis;JC
polyomavirus test positive;JC virus CSF test positive;Jeavons syndrome;Jugular vein
embolism;Jugular vein thrombosis;Juvenile idiopathic arthritis;Juvenile myoclonic
epilepsy;Juvenile polymyositis;Juvenile psoriatic arthritis;Juvenile spondyloarthritis;Kaposi
sarcoma inflammatory cytokine syndrome;Kawasaki's disease;Kayser-Fleischer
ring;Keratoderma blenorrhagica;Ketosisprone diabetes mellitus;Kounis syndrome;Lafora's
myoclonic epilepsy;Lambl's excrescences;Laryngeal dyspnoea;Laryngeal oedema;Laryngeal
rheumatoid arthritis;Laryngospasm;Laryngotracheal oedema;Latent autoimmune diabetes in
adults;LE cells present;Lemierre syndrome;Lennox-Gastaut syndrome;Leucine aminopeptidase
increased;Leukoencephalomyelitis;Leukoencephalopathy;Leukopenia;Leukopenia
neonatal;Lewis-Sumner syndrome;Lhermit e's sign;Lichen planopilaris;Lichen planus;Lichen
sclerosus;Limbic encephalitis;Linear IgA disease;Lip oedema;Lip swelling;Liver function test
abnormal;Liver function test decreased;Liver function test increased;Liver induration;Liver
injury;Liver iron concentration abnormal;Liver iron concentration Page 34
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (
GMT)
FDA-CBER-2021-5683-0000087
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page
6 increased;Liver opacity;Liver palpable;Liver sarcoidosis;Liver scan abnormal;Liver
tenderness;Low birth weight baby;Lower respiratory tract herpes infection;Lower respiratory
tract infection;Lower respiratory tract infection viral;Lung abscess;Lupoid hepatic cirrhosis;Lupus
cystitis;Lupus encephalitis;Lupus endocarditis;Lupus enteritis;Lupus hepatitis;Lupus
myocarditis;Lupus myositis;Lupus nephritis;Lupus pancreatitis;Lupus pleurisy;Lupus
pneumonitis;Lupus vasculitis;Lupus-like syndrome;Lymphocytic hypophysitis;Lymphocytopenia
neonatal;Lymphopenia;MAGIC syndrome;Magnetic resonance imaging liver abnormal;Magnetic
resonance proton density fat fraction measurement;Mahler sign;Manufacturing laboratory
analytical testing issue;Manufacturing materials issue;Manufacturing production issue;Marburg's
variant multiple sclerosis;Marchiafava-Bignami disease;Marine Lenhart syndrome;Mastocytic
enterocolitis;Maternal exposure during pregnancy;Medical device site thrombosis;Medical
device site vasculitis;MELAS syndrome;Meningitis;Meningitis aseptic;Meningitis
herpes;Meningoencephalitis herpes simplex neonatal;Meningoencephalitis
herpetic;Meningomyelitis herpes;MERS-CoV test;MERS-CoV test negative;MERS-CoV test
positive;Mesangioproliferative glomerulonephritis;Mesenteric artery embolism;Mesenteric artery
thrombosis;Mesenteric vein thrombosis;Metapneumovirus infection;Metastatic cutaneous
Crohn's disease;Metastatic pulmonary embolism;Microangiopathy;Microembolism;Microscopic
polyangiitis;Middle East respiratory syndrome;Migraine-triggered seizure;Miliary
pneumonia;Mil er Fisher syndrome;Mitochondrial aspartate aminotransferase increased;Mixed
connective tissue disease;Model for end stage liver disease score abnormal;Model for end
stage liver disease score increased;Molar ratio of total branched-chain amino acid to
tyrosine;Molybdenum cofactor deficiency;Monocytopenia;Mononeuritis;Mononeuropathy
multiplex;Morphoea;Morvan syndrome;Mouth swelling;Moyamoya disease;Multifocal motor
neuropathy;Multiple organ dysfunction syndrome;Multiple sclerosis;Multiple sclerosis
relapse;Multiple sclerosis relapse prophylaxis;Multiple subpial transection;Multisystem
inflammatory syndrome in children;Muscular sarcoidosis;Myasthenia gravis;Myasthenia gravis
crisis;Myasthenia gravis neonatal;Myasthenic syndrome;Myelitis;Myelitis transverse;Myocardial
infarction;Myocarditis;Myocarditis post infection;Myoclonic epilepsy;Myoclonic epilepsy and
ragged-red fibres;Myokymia;Myositis;Narcolepsy;Nasal
herpes;Nasal obstruction;Necrotising herpetic retinopathy;Neonatal Crohn's disease;Neonatal
epileptic seizure;Neonatal lupus erythematosus;Neonatal mucocutaneous herpes
simplex;Neonatal pneumonia;Neonatal seizure;Nephritis;Nephrogenic systemic
fibrosis;Neuralgic amyotrophy;Neuritis;Neuritis cranial;Neuromyelitis optica pseudo
relapse;Neuromyelitis optica spectrum disorder;Neuromyotonia;Neuronal
neuropathy;Neuropathy peripheral;Neuropathy, ataxia, retinitis pigmentosa
syndrome;Neuropsychiatric lupus;Neurosarcoidosis;Neutropenia;Neutropenia
Page 9 of 13
neonatal;Neutropenic colitis;Neutropenic infection;Neutropenic sepsis;Nodular rash;Nodular
vasculitis;Noninfectious myelitis;Noninfective encephalitis;Noninfective
encephalomyelitis;Noninfective oophoritis;Obstetrical pulmonary embolism;Occupational
exposure to communicable disease;Occupational exposure to SARS-CoV-2;Ocular
hyperaemia;Ocular myasthenia;Ocular pemphigoid;Ocular sarcoidosis;Ocular
vasculitis;Oculofacial paralysis;Oedema;Oedema blister;Oedema due to hepatic
disease;Oedema mouth;Oesophageal achalasia;Ophthalmic artery thrombosis;Ophthalmic
herpes simplex;Ophthalmic herpes zoster;Ophthalmic vein thrombosis;Optic neuritis;Optic Page
35 090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (
GMT)
FDA-CBER-2021-5683-0000088
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page
7 neuropathy;Optic perineuritis;Oral herpes;Oral lichen planus;Oropharyngeal
oedema;Oropharyngeal spasm;Oropharyngeal swelling;Osmotic demyelination
syndrome;Ovarian vein thrombosis;Overlap syndrome;Paediatric autoimmune neuropsychiatric
disorders associated with streptococcal infection;Paget-Schroetter syndrome;Palindromic
rheumatism;Palisaded neutrophilic granulomatous dermatitis;Palmoplantar
keratoderma;Palpable purpura;Pancreatitis;Panencephalitis;Papil ophlebitis;Paracancerous
pneumonia;Paradoxical embolism;Parainfluenzae viral laryngotracheobronchitis;Paraneoplastic
dermatomyositis;Paraneoplastic pemphigus;Paraneoplastic thrombosis;Paresis cranial
nerve;Parietal cell antibody positive;Paroxysmal nocturnal haemoglobinuria;Partial
seizures;Partial seizures with secondary generalisation;Patient isolation;Pelvic venous
thrombosis;Pemphigoid;Pemphigus;Penile vein thrombosis;Pericarditis;Pericarditis
lupus;Perihepatic discomfort;Periorbital oedema;Periorbital swelling;Peripheral artery
thrombosis;Peripheral embolism;Peripheral ischaemia;Peripheral vein thrombus
extension;Periportal oedema;Peritoneal fluid protein abnormal;Peritoneal fluid protein
decreased;Peritoneal fluid protein increased;Peritonitis lupus;Pernicious anaemia;Petit mal
epilepsy;Pharyngeal oedema;Pharyngeal swelling;Pityriasis lichenoides et varioliformis
acuta;Placenta praevia;Pleuroparenchymal fibroelastosis;Pneumobilia;Pneumonia;Pneumonia
adenoviral;Pneumonia cytomegaloviral;Pneumonia herpes viral;Pneumonia
influenzal;Pneumonia measles;Pneumonia mycoplasmal;Pneumonia necrotising;Pneumonia
parainfluenzae viral;Pneumonia respiratory syncytial viral;Pneumonia viral;POEMS
syndrome;Polyarteritis nodosa;Polyarthritis;Polychondritis;Polyglandular autoimmune syndrome
type I;Polyglandular autoimmune syndrome type II;Polyglandular autoimmune syndrome type
II ;Polyglandular disorder;Polymicrogyria;Polymyalgia
rheumatica;Polymyositis;Polyneuropathy;Polyneuropathy idiopathic progressive;Portal
pyaemia;Portal vein embolism;Portal vein flow decreased;Portal vein pressure increased;Portal
vein thrombosis;Portosplenomesenteric venous thrombosis;Post procedural hypotension;Post
procedural pneumonia;Post procedural pulmonary embolism;Post stroke epilepsy;Post stroke
seizure;Post thrombotic retinopathy;Post thrombotic syndrome;Post viral fatigue
syndrome;Postictal headache;Postictal paralysis;Postictal psychosis;Postictal
state;Postoperative respiratory distress;Postoperative respiratory failure;Postoperative
thrombosis;Postpartum thrombosis;Postpartum venous thrombosis;Postpericardiotomy
syndrome;Post-traumatic epilepsy;Postural orthostatic tachycardia syndrome;Precerebral artery
thrombosis;Pre-eclampsia;Preictal state;Premature labour;Premature menopause;Primary
amyloidosis;Primary biliary cholangitis;Primary progressive multiple sclerosis;Procedural
shock;Proctitis herpes;Proctitis ulcerative;Product availability issue;Product distribution
issue;Product supply issue;Progressive facial hemiatrophy;Progressive multifocal
leukoencephalopathy;Progressive multiple sclerosis;Progressive relapsing multiple
sclerosis;Prosthetic cardiac valve thrombosis;Pruritus;Pruritus
allergic;Pseudovasculitis;Psoriasis;Psoriatic
arthropathy;Pulmonary amyloidosis;Pulmonary artery thrombosis;Pulmonary
embolism;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary microemboli;Pulmonary oil
microembolism;Pulmonary renal syndrome;Pulmonary sarcoidosis;Pulmonary sepsis;Pulmonary
thrombosis;Pulmonary tumour thrombotic microangiopathy;Pulmonary vasculitis;Pulmonary
veno-occlusive disease;Pulmonary venous thrombosis;Pyoderma gangrenosum;Pyostomatitis
Page 10 of 13
vegetans;Pyrexia;Quarantine;Radiation leukopenia;Radiculitis Page 36
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (
GMT)
FDA-CBER-2021-5683-0000089
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page
8 brachial;Radiologically isolated syndrome;Rash;Rash erythematous;Rash pruritic;Rasmussen
encephalitis;Raynaud's phenomenon;Reactive capil ary endothelial proliferation;Relapsing
multiple sclerosis;Relapsing-remit ing multiple sclerosis;Renal amyloidosis;Renal arteritis;Renal
artery thrombosis;Renal embolism;Renal failure;Renal vascular thrombosis;Renal
vasculitis;Renal vein embolism;Renal vein thrombosis;Respiratory arrest;Respiratory
disorder;Respiratory distress;Respiratory failure;Respiratory paralysis;Respiratory syncytial
virus bronchiolitis;Respiratory syncytial virus bronchitis;Retinal artery embolism;Retinal artery
occlusion;Retinal artery thrombosis;Retinal vascular thrombosis;Retinal vasculitis;Retinal vein
occlusion;Retinal vein thrombosis;Retinol binding protein decreased;Retinopathy;Retrograde
portal vein flow;Retroperitoneal fibrosis;Reversible airways obstruction;Reynold's
syndrome;Rheumatic brain disease;Rheumatic disorder;Rheumatoid arthritis;Rheumatoid factor
increased;Rheumatoid factor positive;Rheumatoid factor quantitative increased;Rheumatoid
lung;Rheumatoid neutrophilic dermatosis;Rheumatoid nodule;Rheumatoid nodule
removal;Rheumatoid scleritis;Rheumatoid vasculitis;Saccadic eye movement;SAPHO
syndrome;Sarcoidosis;SARS-CoV-1 test;SARS-CoV-1 test negative;SARS-CoV-1 test
positive;SARS-CoV-2 antibody test;SARS-CoV-2 antibody test negative;SARS-CoV-2 antibody
test positive;SARS-CoV-2 carrier;SARS-CoV-2 sepsis;SARS-CoV-2 test;SARSCoV-
2 test false negative;SARS-CoV-2 test false positive;SARS-CoV-2 test negative;SARSCoV-
2 test positive;SARS-CoV-2 viraemia;Satoyoshi
syndrome;Schizencephaly;Scleritis;Sclerodactylia;Scleroderma;Scleroderma associated digital
ulcer;Scleroderma renal crisis;Scleroderma-like reaction;Secondary amyloidosis;Secondary
cerebellar degeneration;Secondary progressive multiple sclerosis;Segmented hyalinising
vasculitis;Seizure;Seizure anoxic;Seizure cluster;Seizure like phenomena;Seizure
prophylaxis;Sensation of foreign body;Septic embolus;Septic pulmonary embolism;Severe
acute respiratory syndrome;Severe myoclonic epilepsy of infancy;Shock;Shock
symptom;Shrinking lung syndrome;Shunt thrombosis;Silent thyroiditis;Simple partial
seizures;Sjogren's syndrome;Skin swelling;SLE arthritis;Smooth muscle antibody
positive;Sneezing;Spinal artery embolism;Spinal artery thrombosis;Splenic artery
thrombosis;Splenic embolism;Splenic thrombosis;Splenic vein
thrombosis;Spondylitis;Spondyloarthropathy;Spontaneous heparin-induced thrombocytopenia
syndrome;Status epilepticus;Stevens-Johnson syndrome;Stif leg syndrome;Stif person
syndrome;Stillbirth;Still's disease;Stoma site thrombosis;Stoma site vasculitis;Stress
cardiomyopathy;Stridor;Subacute cutaneous lupus erythematosus;Subacute
endocarditis;Subacute inflammatory demyelinating polyneuropathy;Subclavian artery
embolism;Subclavian artery thrombosis;Subclavian vein thrombosis;Sudden unexplained death
in epilepsy;Superior sagittal sinus thrombosis;Susac's syndrome;Suspected COVID-
19;Swelling;Swelling face;Swelling of eyelid;Swollen tongue;Sympathetic ophthalmia;Systemic
lupus erythematosus;Systemic lupus erythematosus disease activity index abnormal;Systemic
lupus erythematosus disease activity index decreased;Systemic lupus erythematosus disease
activity index increased;Systemic lupus erythematosus rash;Systemic scleroderma;Systemic
sclerosis pulmonary;Tachycardia;Tachypnoea;Takayasu's arteritis;Temporal lobe
epilepsy;Terminal ileitis;Testicular autoimmunity;Throat tightness;Thromboangiitis
obliterans;Thrombocytopenia;Thrombocytopenic
purpura;Thrombophlebitis;Thrombophlebitis migrans;Thrombophlebitis Page 37
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (
GMT)
FDA-CBER-2021-5683-0000090
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports CONFIDENTIAL Page
9 neonatal;Thrombophlebitis septic;Thrombophlebitis superficial;Thromboplastin antibody
positive;Thrombosis;Thrombosis corpora cavernosa;Thrombosis in device;Thrombosis
Page 11 of 13
mesenteric vessel;Thrombotic cerebral infarction;Thrombotic microangiopathy;Thrombotic
stroke;Thrombotic thrombocytopenic purpura;Thyroid disorder;Thyroid stimulating
immunoglobulin increased;Thyroiditis;Tongue amyloidosis;Tongue biting;Tongue oedema;Tonic
clonic movements;Tonic convulsion;Tonic posturing;Topectomy;Total bile acids increased;Toxic
epidermal necrolysis;Toxic leukoencephalopathy;Toxic oil syndrome;Tracheal
obstruction;Tracheal oedema;Tracheobronchitis;Tracheobronchitis
mycoplasmal;Tracheobronchitis viral;Transaminases abnormal;Transaminases
increased;Transfusion-related alloimmune neutropenia;Transient epileptic amnesia;Transverse
sinus thrombosis;Trigeminal nerve paresis;Trigeminal neuralgia;Trigeminal palsy;Truncus
coeliacus thrombosis;Tuberous sclerosis complex;Tubulointerstitial nephritis and uveitis
syndrome;Tumefactive multiple sclerosis;Tumour embolism;Tumour thrombosis;Type 1
diabetes mellitus;Type I hypersensitivity;Type I I immune complex mediated reaction;Uhthoff's
phenomenon;Ulcerative keratitis;Ultrasound liver abnormal;Umbilical cord thrombosis;Uncinate
fits;Undif erentiated connective tissue disease;Upper airway obstruction;Urine bilirubin
increased;Urobilinogen urine decreased;Urobilinogen urine increased;Urticaria;Urticaria
papular;Urticarial vasculitis;Uterine rupture;Uveitis;Vaccination site thrombosis;Vaccination site
vasculitis;Vagus nerve paralysis;Varicella;Varicella keratitis;Varicella post vaccine;Varicella
zoster gastritis;Varicella zoster oesophagitis;Varicella zoster pneumonia;Varicella zoster
sepsis;Varicella zoster virus infection;Vasa praevia;Vascular graft thrombosis;Vascular
pseudoaneurysm thrombosis;Vascular purpura;Vascular stent thrombosis;Vasculitic
rash;Vasculitic ulcer;Vasculitis;Vasculitis gastrointestinal;Vasculitis necrotising;Vena cava
embolism;Vena cava thrombosis;Venous intravasation;Venous recanalisation;Venous
thrombosis;Venous thrombosis in pregnancy;Venous thrombosis limb;Venous thrombosis
neonatal;Vertebral artery thrombosis;Vessel puncture site thrombosis;Visceral venous
thrombosis;VIth nerve paralysis;VIth nerve paresis;Vitiligo;Vocal cord paralysis;Vocal cord
paresis;Vogt-Koyanagi-Harada disease;Warm type haemolytic anaemia;Wheezing;White nipple
sign;XIth nerve paralysis;X-ray hepatobiliary abnormal;Young's syndrome;Zika virus associated
Guil ain Barre syndrome.
Page 38 090177e196ea1800\
Request – 7 December 2021 12.58pm
The below webpage shows a list of 271 generic drugs known to interact with Pfizer’s vaccine.
270 of them are moderate interactions meaning:
“Moderately clinically significant. Usually avoid combinations; use it only under special
circumstances.”
Question: Does the Govt regard this as misinformation please?
https:/ scanmail.trustwave.com/?c=15517&d=4KOu4QHKqKP8GqmPUfENVCX2029rI5rnigQUL
zVAzQ&u=https%3a%2f%2fwww%2edrugs%2ecom%2fdrug-interactions%2fsars-cov-2-mrna-
tozinameran-vaccine%2cpfizer-biontech-covid-19-vaccine-index%2ehtml
Request – 10 December 2021 11.03am (transferred from the Minister of Health)
Regarding the Risk Management Plan for Comirnaty:
https://www.medsafe.govt.nz/COVID-19/Comirnaty-RMP.pdf
The plan refers to Table 1: List of important risks and missing information.
Missing Information:
-Use in pregnancy and while breast feeding -Use in immunocompromised patients -Use in frail
patients with co-morbidities (eg, chronic obstructive pulmonary disease [COPD], diabetes,
Page 12 of 13
chronic neurological disease, cardiovascular disorders) -Use in patients with autoimmune or
inflammatory disorders -Interaction with other vaccines -Long-term safety data
Please can you advise when the “missing information” wil be available to the public.
You have a year of real world data to inform you.
Request – 10 December 2021 11.19am (transferred from the Minister of Health)
In Medsafe’s data sheet for Pfizer’s vaccine it mentions the below under:
4.6 Fertility, pregnancy and lactation
Fertility
“In a combined fertility and developmental toxicity study, female rats were intramuscularly
administered COMIRNATY prior to mating and during gestation (4 full human doses of 30 μg
each, spanning between pre-mating day 21 and gestation day 20). SARS-CoV-2 neutralising
antibodies were present in maternal animals from prior to mating to the end of the study on
postnatal day 21 as well as in fetuses and of spring. There were no vaccine related effects on
female fertility and pregnancy rate.”
Pregnancy
“Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy,
embryo/fetal development, parturition or post-natal development.”
https://www.medsafe.govt.nz/profs/Datasheet/c/comirnatyinj.pdf
Question please:
What were the miscarriage and stil birth rates among the rats that were studied?
Request – 23 December 2021 (transferred from the DPMC)
“When did the Prime Minister receive the post-marketing information from Pfizer?”
Request – 16 December 2021
I understand serialization, in the context of a vaccine rollout, involves the identification of
vaccine batches for the purposes of tracking and research.
Is the NZ Govt serializing the Pfizer vaccine batches for efficacy and safety purposes please?
Request – 20 December 2021
On the Japanese “Instructions for the Covid-19 vaccination” it states:
“This product contains an additive that has never been used in a vaccine before.”
https:/ scanmail.trustwave.com/?c=15517&d=m4e_4YQtPbuqbvNRzgcgEBSwnQ2jLgcFBRpC4
T3XUA&u=https%3a%2f%2fwww%2emhlw%2ego%2ejp%2fcontent%2f000759294%2epdf
My questions please:
1)
Does the Comirnaty vaccine used in NZ contain this additive?
3)
If so what is it?
Page 13 of 13
